Major World Markets for Stents and The Economics of Drug-Eluting Technology

Table of Contents

• Background
• Scope and Methodology
• Size and Growth of Market

• Background
• Stents, Coatings and Subacute Thrombosis
• Drug Eluting Stent Technology
• Problems
• Alternatives to Drug -Eluting Stents
  • Branchytherapy
  • Biochemical Approaches
  • Pharmaceutical Approaches

• Direct and Indirect Costs of Stents
• ACC Study
• Factors behind Drug Eluding Stent Adoption
• Price of Stents
• Restenosis and Mortality

• Demographics
  • Population
  • Age
  • Sex
  • Race and Ethnicity
• Public Health Issues
  • Obesity
  • Smoking
  • Hypertension
• Economics
• Political Factors
• Market Estimates
• The Upstarts

• Overview
• Abbott Vascular
• Atrium Medical Corporation
• Boston Scientific
• CeloNova Biosciences
• Conor Medsystems (A Johnson & Johnson Company)
• Cordis Corporation (A Johnson & Johnson Company)
• Medinol Ltd.
• Medtronic, Inc.
• MIV Therapeutics, Inc.
• OrbusNeich
• Stentys S.A.S.
• Terumo Medical Corporation
• XTENT, Inc.

• First Conclusion
  • Implications
• Second Conclusion
  • Implications
• Third Conclusion
  • Implications
• Fourth Conclusion
  • Implications
• Fifth Conclusion
  • Implications
• Sixth Conclusion
  • Implications
• Seventh Conclusion
  • Implications
• Eighth Conclusion
  • Implications
• Ninth Conclusion
  • Implications

• Table 1-1: Projected Deaths from Ischemic Heart Disease (IHD) and Acute Myocardial Infarction (AMI) in the Seven Major World Healthcare Markets: 2008
• Table 1-2: The Estimated Total Market for Coronary Stents in the Seven Major World Healthcare Markets: 2008, 2013 and 2018
• Table 1-3: The Estimated Market for Bare Metal Coronary Stents in the Seven Major World Healthcare Markets: 2008, 2013 and 2018
• Table 1-4: The Estimated Market for Drug-Eluting Coronary Stents in the Seven Major World Healthcare Markets: 2008, 2013 and 2018
• Figure 1-1: Trending in the Estimated Total Market for Coronary Stents in the Seven Major World Healthcare Markets: 2008, 2013 and - 2018
• Figure 1-2: Trending in the Estimated Market for Bare Metal Coronary Stents in the Seven Major World Healthcare Markets: 2008, 2013 and 2018
• Figure 1-3: Trending in the Estimated Market for Drug-Eluting Coronary Stents in the Seven Major World Healthcare Markets: 2008, 2013 and 2018

• Table 2-1: Top Ten Major Causes of Death in the World By Region
• Table 2-2: Top Ten Major Causes of Death in the World By Regional Development Level: (Developing Countries, Developed Countries) 2001
• Table 2-3: Top Ten Major Causes of Death in the World By Income Level: 2001
• Figure 2-1: Percentages of Deaths related to Cardiovascular Diseases in the Seven Major World Healthcare Markets: 2001
• Table 2-4:Projected Deaths from Ischemic Heart Disease (IHD) and Acute Myocardial Infarction (AMI) in the Seven Major World Healthcare Markets: 2008
• Figure 2-2: Distribution of Projected Ischemic Heart Disease Fatalities in the Seven Major World Healthcare Markets: 2008
• Figure 2-3: Distribution of Projected Acute Myocardial Infarction Fatalities in the Seven Major World Healthcare Markets: 2008

• Table 3-1: Economic Burden (Direct Costs) of Restenosis
• Table 3-2: Medicare Trends in Coronary Revascularization Therapy
• Figure 3-1: Projected Two-Year Cardiovascular Cost Impact of Background Restenosis Rate
• Figure 3-2: Cost Per Quality-Adjusted Year of Life Saved for Some Healthcare Investments: Preventive and Therapeutic
• Table 3-3: Cost Per Repeated Revascularization Avoided
• Table 3-4: Willingness to Pay for Restenosis Prevention Technology
• Table 3-5: Predicted Clinical Restenosis Rates Following PTCA and Stent
• Table 3-6: Expected Cost-Effectiveness of Drug-Eluting Stents

• Table 4-1: IHD/CHD Heart Disease Age-Standardized Mortality Rates* for Both Sexes
• Figure 4-1: Projected IHD/CHD Cases: 2008
• Table 4-2: Projected Populations of the Seven Major World Markets: 2008 - 2018
• Figure 4-2(a): Trending in the Populations of the Five Major European Healthcare Markets: 2008 - 2018
• Figure 4-2(b): Trending in the Populations of Japan and the United States: 2008 - 2018
• Table 4-3: Ranking of the Major Causes of Death by Age Group in the United States: 2003
• Table 4-4: Trends in the Older (60+) Populations of the Seen Major World Healthcare Markets: 1950 - 2050
• Figure 4-3: Trending in the 60+ Year Old Population of the Seven Major World Healthcare Markets: 1950 - 2050
• Figure 4-4: Trending in the Percentage of the General Population that is 60+ Years Old in the Seven Major World Healthcare Markets: 1950 - 2050
• Table 4-5: Increases in IHD/CHD Incidence* with Age
• Table 4-6: Crude Death Rates* Associated with CVD: 2004
• Table 4-7: Crude Death Rates* Associated with IHD/CHD: 2006
• Table 4-8: Expected Death Rates* from IHD/CHD and AMI for Men and Women in the Seven Major World Healthcare Markets: 2008
• Table 4-9: Death Rates* for CVD for Men by Race and Ethnicity in the United States: 1985 - 2002
• Table 4-10: Death Rates* for CVD for Women by Race and Ethnicity in the United States: 1985 - 2002
• Table 4-11: Major Causes of Death for White, Black, American Indian and Hispanic Males in the United States: 2004
• Table 4-12: Major Causes of Death for White, Black, American Indian and Hispanic Females in the United States: 2004
• Table 4-13: Deaths from CVD for White and Black Men in the United States by Age Group: 2004
• Table 4-14: Deaths from CVD for White and Black Women in the United States by Age Group: 2004
• Figure 4-5: Trending in the Percentage Differences in CVD Deaths of Black Men and Women over those of White Men and Women by Age Group: 2004
• Table 4-15: Percentage of Obesity in the Seven Major World Healthcare Markets: 2005
• Table 4-16: Prevalence of Obesity in the Seven Major World Healthcare Markets: 2004
• Figure 4-6: Age-Adjusted Prevalence of Obesity* in Adult Americans (Ages 20 to 74) by Sex: 1960 - 2004
• Table 4-17: Smoking Prevalence in the Seven Major World Healthcare Markets (Standardized Data - % of Population)
• Figure 4-7: Prevalence of Hypertension in Americans Age 20 Years and Older by Age and Sex
• Table 4-18: Cost Estimates of Revascularization Using Drug-Eluting Stents versus Bare Metal Stents: 2003
• Table 4-19: The Estimated Total Market for Coronary Stents in the Seven Major World Healthcare Markets: 2008 - 2018
• Table 4-20: The Estimated Market for Bare Metal Coronary Stents in the Seven Major World Healthcare Markets: 2008 - 2018
• Table 4-21: The Estimated Market for Drug-Eluting Coronary Stents in the Seven Major World Healthcare Markets: 2008 - 2018
• Figure 4-8: Trending in the Estimated Total Market for Coronary Stents in the Seven Major World Healthcare Markets: 2008 - 2018
• Figure 4-9: Trending in the Estimated Market for Bare Metal Coronary Stents in the Seven Major World Healthcare Markets: 2008 - 2018
• Figure 4-10: Trending in the Estimated Market for Drug-Eluting Coronary Stents in the Seven Major World Healthcare Markets: 2008 - 2018
• Figure 4-11: Estimated Coronary Stent Market Average Annual Growth Rates in the Seven Major World Healthcare Markets: 2008 - 2018
• Figure 4-12: Distribution of the Estimated Total Market for Coronary Stents in the Seven Major World Healthcare Markets: 2008 - 2018